Insulet Corporation (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Insulet Corporation (NASDAQ:PODD) have been given a consensus recommendation of “Moderate Buy” by the twenty-three analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, twenty have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $379.65.

A number of research analysts have issued reports on PODD shares. Raymond James Financial lifted their target price on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Wolfe Research upped their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. UBS Group upgraded shares of Insulet from a “neutral” rating to a “buy” rating and raised their target price for the company from $355.00 to $400.00 in a research report on Wednesday, November 19th. Finally, BTIG Research upped their price target on shares of Insulet from $370.00 to $380.00 and gave the stock a “buy” rating in a report on Friday, November 21st.

Insulet Stock Down 0.5%

Shares of PODD opened at $307.56 on Thursday. The firm has a 50 day simple moving average of $320.73 and a two-hundred day simple moving average of $316.08. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. Insulet has a one year low of $230.05 and a one year high of $354.88. The company has a market cap of $21.64 billion, a P/E ratio of 89.15, a P/E/G ratio of 2.19 and a beta of 1.37.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same quarter last year, the business posted $1.08 EPS. The company’s revenue was up 29.9% compared to the same quarter last year. Research analysts forecast that Insulet will post 3.92 EPS for the current fiscal year.

Insider Transactions at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insulet

Several large investors have recently modified their holdings of the business. Sage Mountain Advisors LLC raised its position in Insulet by 4.6% during the 3rd quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 33 shares during the last quarter. Glenmede Investment Management LP increased its stake in shares of Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares during the period. Curi Capital LLC raised its position in shares of Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares during the last quarter. WINTON GROUP Ltd lifted its stake in shares of Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after acquiring an additional 37 shares during the period. Finally, Evelyn Partners Investment Management Services Ltd boosted its holdings in Insulet by 28.7% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 39 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.